{"id":"NCT00835380","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)","officialTitle":"A Phase III Open-Label Study of Immunogenicity, Safety, and Tolerability of 2 Doses of VAQTA™ (Formalin, Inactivated, Alum-Adjuvanted Hepatitis A Vaccine) in Healthy Children 12 to 23 Months of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2009-02-03","resultsPosted":"2010-01-11","lastUpdate":"2017-04-13"},"enrollment":80,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis A Virus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Hepatitis A Vaccine, Purified Inactivated (VAQTA™)","otherNames":["VAQTA™"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This study will demonstrate the immunogenicity and evaluate the safety/tolerability of the vaccine in Chinese children between 12 and 23 months of age.","primaryOutcome":{"measure":"Hepatitis A Virus (HAV) Seroconversion Rate, i.e. the Percentage of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7 After Administration of a 2-dose Regime of Vaccines.","timeFrame":"Collect blood sample for HAV antibody testing at Day 0 prior to vaccination, and Month 7 (4 weeks after administration of a 2-dose regimen of vaccines at Month 6)","effectByArm":[{"arm":"VAQTA™","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":["Fever","Upper respiratory tract infection","Diarrhea","Coughing","Injection site redness"]}}